Overview

DAS181 for Severe COVID-19: Compassionate Use

Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Phase:
N/A
Details
Lead Sponsor:
Renmin Hospital of Wuhan University
Collaborator:
Ansun Biopharma, Inc.